Search Within

Jonathan Eric Rosenberg

Formats
  1. Meeting Abstract (283)
  2. Journal Article (195)
  3. Review (18)
  4. Correspondence (10)
  5. Editorial (5)
  6. Guidelines (4)
  7. Book Section (2)
  8. Research Letter (2)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (520)
  2. Genitourinary Oncology Service (520)
  3. Solid Tumor Oncology Division (520)
  4. Department of Pathology and Laboratory Medicine (149)
  5. Surgery (140)
  6. Urology (137)

More Groups

People
  1. Dean Bajorin (204)
  2. Gopakumar Iyer (175)
  3. Hikmat Al-Ahmadie (134)
  4. Bernard Bochner (124)
  5. David Solit (114)
  6. Min Yuen Teo (75)

More People

Years
  1. 2025 (23)
  2. 2024 (36)
  3. 2023 (32)
  4. 2022 (36)
  5. 2021 (48)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (204)
  2. Annals of Oncology (42)
  3. European Urology (20)
  4. Clinical Genitourinary Cancer (18)
  5. Clinical Cancer Research (16)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (210)
  2. Oxford University Press (47)
  3. Elsevier Inc. (39)
  4. Elsevier Science, Inc. (36)
  5. Nature Publishing Group (36)
  6. American Association for Cancer Research (35)

More Publishers

Results (520)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Enfortumab vedotin and pembrolizumab: Redefining the standard of care for previously untreated advanced urothelial cancer
    Review

    Sternschuss, M.; Rosenberg, J. E.
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker-based study (Alliance A032102)
    Meeting Abstract

    McKay, R. R.; Heller, G.; Zhao, S.; Wulff-Burchfield, E. M.; Shah, D.; Tan, A.; Galsky, M. D.; Rosenberg, J. E.; Beltran, H.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Survey-based study of treatment sequencing after first-line (1L) enfortumab vedotin/pembrolizumab (EVP) in the evolving landscape of locally advanced/metastatic (la/m) urothelial cancer (UC)
    Meeting Abstract

    Chablani, P. V.; Khaki, A. R.; Tawagi, K.; Grivas, P.; Hoffman-Censits, J.; Galsky, M. D.; Gupta, S.; Koshkin, V. S.; Plimack, E. R.; Rosenberg, J. E.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Preferred treatment regimens for rare genitourinary (GU) malignancies
    Meeting Abstract

    Simon, N. I.; Berg, S. A.; Tan, A.; Chandran, E.; Atiq, S. O.; Kydd, A. R.; Cordes, L. M.; Mortazavi, A.; Reimers, M. A.; Milowsky, M. I.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC)
    Meeting Abstract

    Gupta, A.; Sevilla, C.; Pihlstrom, N. L.; Liang, S.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Wong, P.; Ahmed, F.; Funt, S. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Updated long-term follow-up from a phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma
    Meeting Abstract

    Jayalath, V.; Teo, M. Y.; Assel, M.; Rodriguez, D.; Meyerson, A.; Bochner, B. H.; Dalbagni, G.; Donat, S. M.; Herr, H. W.; Cha, E. K.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Correlation of NECTIN4 amplification and expression with response to enfortumab vedotin (EV) treatment in locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Yol, C.; Irawan, H.; Sternschuss, M.; Gupta, A.; Bent, E.; Basar, M.; Chen, J. F.; Sarungbam, J.; Chen, Y. B.; Gopalan, A.; more...
    Laboratory Investigation (2025)

    Fulltext@MSK | Save
  • Circulating tumor DNA and response to cisplatin-based chemotherapy in patients with metastatic urothelial carcinoma enrolled in CALGB 90601 (Alliance)
    Journal Article

    Guercio, B. J.; Whiting, K.; Shah, R. H.; Ballman, K. V.; Halabi, S.; Regazzi, A. M.; Milbank, J. H.; Bajorin, D. F.; Beltran, H.; Morris, M. J.; more...
    European Urology Open Science (2025)

    Fulltext@MSK | Save
  • Correlative science from a phase I study of intravesical Fc-optimized anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)
    Meeting Abstract

    Bochner, B. H.; Alam, S. M.; Blanchard, L.; Yao, N.; Angulo-Lozano, J.; Wong, J.; Knorr, D.; Whiting, K.; Seshan, V.; Donahue, T.; more...
    Urologic Oncology: Seminars and Original Investigations (2025)

    Fulltext@MSK | Save
  • Transcriptional analysis of bladder cancer histologic subtypes reveals novel drug target heterogeneity
    Meeting Abstract

    Tallman, J. E.; Kuo, F.; Koll, F.; Alam, S. M.; Basar, M.; Luo, J.; Gao, S. P.; Tang, X.; Yol, C.; Gokturk, G.; more...
    Urologic Oncology: Seminars and Original Investigations (2025)

    Fulltext@MSK | Save